期刊
FRONTIERS IN IMMUNOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.01854
关键词
biomarker; GVHD; steroid-refractory graft-vs; -host disease; immune cells; relapse; minimal residual disease
类别
资金
- Deutsche Forschungsgemeinschaft, Germany
- Deutsche Forschungsgemeinschaft [SFB TRR167, SFB 850]
- ERC Consolidator grant [681012]
- Germany's Excellence Strategy [CIBSS - EXC-2189, 390939984]
- European Research Council (ERC) [681012] Funding Source: European Research Council (ERC)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a well-established curative treatment for various malignant hematological diseases. However, its clinical success is substantially limited by major complications including graft-vs.-host disease (GVHD) and relapse of the underlying disease. Although these complications are known to lead to significant morbidity and mortality, standardized pathways for risk stratification of patients undergoing allo-HSCT are lacking. Recent advances in the development of diagnostic and prognostic tools have allowed the identification of biomarkers in order to predict outcome after allo-HSCT. This review will provide a summary of clinically relevant biomarkers that have been studied to predict the development of acute GVHD, the responsiveness of affected patients to immunosuppressive treatment and the risk of non-relapse mortality. Furthermore, biomarkers associated with increased risk of relapse and subsequent mortality will be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据